Cardiovascular Disease
Most recent (10)
Article
""

Easing the impact of GLP-1s

With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.

Kasey Raetz, PharmD, January 11, 24

Read More
Article
""

Chronic conditions: The impact of delayed detection

Early detection of chronic diseases matters to the bottom line.

Viju Paul, RPh, December 19, 23

Read More
Article
""

Study: Cardiodiabesity prevention key to improving health outcomes and lowering costs

The Evernorth Research Institute analyzed aggregated and anonymized data of almost 5 million insured individuals to understand the prevalence of "cardiodiabesity" — a condition which encompasses cardi...

September 07, 23

Read More
Article
""

Designing plans to manage comorbid conditions

Health plans that address and manage complex chronic conditions such as cardiovascular disease, obesity, and diabetes have a competitive advantage.

Daniel Chambers, PharmD., August 25, 23

Read More
Article
""

Addressing obesity in the workplace

As more people turn to diabetes medication to manage their weight, obesity has become a pressing concern for employers.

Christine Gilroy, MD, MSPH, July 26, 23

Read More
Video
""

Clinically Speaking: GLP-1s Medications 101

GLP-1 medications are FDA-approved specifically for weight loss for more than half the adult population in the United States. Plan sponsors can take action to manage weight and other cardiodiabesity-r...

Christine Gilroy, MD, MSPH, July 25, 23

Read More